Show simple item record

dc.contributor.authorPerrotti, D.
dc.contributor.authorAgarwal, A.
dc.contributor.authorLucas, C.M.
dc.date.accessioned2019-08-16T14:01:02Z
dc.date.available2019-08-16T14:01:02Z
dc.date.issued2019
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85069912263&doi=10.1126%2fscitranslmed.aau0416&partnerID=40&md5=4dbc1da010bf94217da9296cc4c89105
dc.identifier.urihttp://hdl.handle.net/10713/10369
dc.description.abstractLB100 does not sensitize CML stem cells to tyrosine kinase inhibitor-induced apoptosis. Copyright 2019 The Authors.en_US
dc.description.urihttps://www.doi.org/10.1126/scitranslmed.aau0416en_US
dc.language.isoen-USen_US
dc.publisherAmerican Association for the Advancement of Scienceen_US
dc.relation.ispartofScience Translational Medicine
dc.subject.meshLeukemiaen_US
dc.subject.meshNeoplastic Stem Cellsen_US
dc.titleComment on "pP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia"en_US
dc.typeArticleen_US
dc.identifier.doi10.1126/scitranslmed.aau0416


This item appears in the following Collection(s)

Show simple item record